Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsBlue Cross Iowa Ojjaara Policy Update | OpenPayer
    Ask Trek AI about this page
    CurrentBlue Cross Blue Shield - IowaPolicy 05.05.23

    Ojjaara (momelotinib) Coverage Criteria

    Customize your policy alerts

    Sign up for Blue Cross Blue Shield - Iowa Policy 05.05.23 alerts

    Get alerted when Policy 05.05.23 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Prior authorization and medical-necessity coverage for Ojjaara (momelotinib) in adults with myelofibrosis, myelofibrosis-associated anemia, myeloproliferative neoplasms, or myeloid/lymphoid neoplasms with eosinophilia, subject to clinical criteria, documentation requirements, continuation requirements, and quantity limits.

    Policy Summary
    PayerBlue Cross Blue Shield - Iowa
    PolicyOjjaara (momelotinib) Coverage Criteria
    Policy CodePolicy 05.05.23
    Change TypeNo material change
    Effective DateSeptember 14, 2026
    Last ReviewAug 1, 2026
    Next Review DateN/A
    Key ActionSubmit applicable JAK2 rearrangement testing or analysis and documentation showing that the member meets the relevant initial-approval criteria.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    12 monthsStandard initial and continuation authorization period
    30/30 daysQuantity limit per tablet strength
    4Listed compendial-use categories
    JAK2 rearrangementRequired testing where applicable

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Coverage Criteria

    Initial therapy: myelofibrosis and myeloproliferative neoplasms

    Authorization for 12 months may be granted when any of the following criteria are met.

    At least one criterion must be met

    • Intermediate-risk myelofibrosis with anemia: The member has intermediate-risk myelofibrosis with anemia
    • High-risk myelofibrosis: The member has high-risk myelofibrosis with anemia or symptomatic splenomegaly and/or constitutional symptoms, such as fatigue, night sweats, fever, or weight loss
    • Myelofibrosis-associated anemia: The member has myelofibrosis-associated anemia with symptomatic splenomegaly and/or constitutional symptoms, such as fatigue, night sweats, fever, or weight loss
    • Accelerated-phase or blast-phase myeloproliferative neoplasm: The member has symptomatic accelerated-phase or blast-phase myeloproliferative neoplasm, and the requested agent will be used as a single agent or in combination with azacitidine or decitabine

    Initial therapy: myeloid/lymphoid neoplasms with eosinophilia

    Authorization for 12 months may be granted when all of the following conditions are met.

    Myeloid/lymphoid neoplasms with eosinophilia

    • Disease characteristics: The member has a myeloid and/or lymphoid neoplasm with eosinophilia and JAK2 rearrangement in blast or chronic phase
    • Ruxolitinib availability or tolerance

      • Ruxolitinib (Jakafi) is unavailable
      • The member has experienced intolerance to ruxolitinib (Jakafi)

    Continuation therapy: myelofibrosis and myeloproliferative neoplasms

    Authorization for 12 months may be granted for reauthorization when the following condition is met.

    Continued treatment: The member is requesting continued treatment for myelofibrosis, myelofibrosis-associated anemia, or myeloproliferative neoplasm, and there is no evidence of unacceptable toxicity

    Continuation therapy: myeloid/lymphoid neoplasms with eosinophilia

    Authorization for 12 months may be granted for reauthorization when all of the following conditions are met.

    Continued treatment: The member is requesting continued treatment for myeloid and/or lymphoid neoplasm with eosinophilia, with no evidence of unacceptable toxicity or disease progression while on the current regimen

    Ojjaara (momelotinib) is considered not medically necessary when the member does not meet the applicable coverage criteria in this policy.

    Initial Therapy Criteria

    Initial therapy: myelofibrosis and myeloproliferative neoplasms

    Authorization of 12 months may be granted for treatment of myelofibrosis, myelofibrosis-associated anemia, or myeloproliferative neoplasm when at least one of the following criteria is met.

    At least one criterion must be met

    • Intermediate-risk myelofibrosis with anemia: The member has intermediate-risk myelofibrosis with anemia
    • High-risk myelofibrosis: The member has high-risk myelofibrosis with anemia or symptomatic splenomegaly and/or constitutional symptoms, such as fatigue, night sweats, fever, or weight loss
    • Myelofibrosis-associated anemia: The member has myelofibrosis-associated anemia with symptomatic splenomegaly and/or constitutional symptoms, such as fatigue, night sweats, fever, or weight loss

    Continuation Therapy Criteria

    Continuation: myelofibrosis and myeloproliferative neoplasms

    Authorization of 12 months may be granted for continued treatment when there is no evidence of unacceptable toxicity.

    Ongoing authorization: The member is requesting reauthorization for myelofibrosis, myelofibrosis-associated anemia, or myeloproliferative neoplasm and has no unacceptable toxicity

    Continuation: myeloid/lymphoid neoplasms with eosinophilia

    Authorization of 12 months may be granted for continued treatment when there is no evidence of unacceptable toxicity or disease progression.

    Ongoing authorization

    • The member is requesting reauthorization for myeloid and/or lymphoid neoplasm with eosinophilia
    • There is no evidence of unacceptable toxicity while on the current regimen

    Step Therapy Requirement

    StepPrerequisiteCondition
    1Ruxolitinib (Jakafi)Must be unavailable or the member must have experienced intolerance to ruxolitinib for myeloid and/or lymphoid neoplasms with eosinophilia and JAK2 rearrangement in blast or chronic phase.

    Quantity Limits

    Quantity Limits
    MedicationOjjaara (momelotinib) 100 mg tablets
    Quantity limit30 per 30 days
    Quantity Limits
    MedicationOjjaara (momelotinib) 150 mg tablets
    Quantity limit30 per 30 days
    Quantity Limits
    MedicationOjjaara (momelotinib) 200 mg tablets

    Provider Actions and Authorization Risks

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required to initiate Ojjaara (momelotinib) treatment. Submit clinical documentation supporting the applicable indication and initial-approval criteria; authorization may be granted for 12 months when criteria are met.

    • Intermediate-risk myelofibrosis with anemia.
    • High-risk myelofibrosis with anemia, symptomatic splenomegaly, and/or constitutional symptoms such as fatigue, night sweats, fever, or weight loss.
    • Myelofibrosis-associated anemia with symptomatic splenomegaly and/or constitutional symptoms such as fatigue, night sweats, fever, or weight loss.
    • Symptomatic accelerated-phase or blast-phase myeloproliferative neoplasms, when Ojjaara is used alone or with azacitidine or decitabine.
    • Myeloid and/or lymphoid neoplasms with eosinophilia in blast or chronic phase when the ruxolitinib exception described below applies.
    Step Therapy

    Ruxolitinib Unavailable or Not Tolerated

    Procedures and Billing Codes

    Procedures and Billing Codesmixed
    N/AN/A

    Background

    Ojjaara (momelotinib) is indicated for adults with intermediate- or high-risk myelofibrosis, including primary myelofibrosis and secondary myelofibrosis following polycythemia vera or essential thrombocythemia, when anemia is present. The policy also recognizes use for symptomatic or high-risk myelofibrosis, myelofibrosis-associated anemia, accelerated- or blast-phase myeloproliferative neoplasms, and myeloid/lymphoid neoplasms with eosinophilia.

    Policy Summary
    PayerBlue Cross Blue Shield - Iowa
    PolicyOjjaara (momelotinib) Coverage Criteria
    Policy CodePolicy 05.05.23
    Change TypeNo material change
    Effective DateSeptember 14, 2026
    Last ReviewAug 1, 2026
    Next Review DateN/A
    Key ActionSubmit applicable JAK2 rearrangement testing or analysis and documentation showing that the member meets the relevant initial-approval criteria.
    SourceLink
    On This Page
    Coverage CriteriaInitial Therapy CriteriaContinuation Therapy CriteriaStep Therapy RequirementQuantity LimitsProvider Actions and Authorization RisksProcedures and Billing CodesBackground
    Accelerated-phase or blast-phase myeloproliferative neoplasm: The member has symptomatic accelerated-phase or blast-phase myeloproliferative neoplasm, and the requested agent will be used as a single agent or in combination with azacitidine or decitabine

    Initial therapy: myeloid/lymphoid neoplasms with eosinophilia

    Authorization of 12 months may be granted for myeloid/lymphoid neoplasms with eosinophilia when all of the following conditions are met.

    Myeloid/lymphoid neoplasms with eosinophilia

    • Disease characteristics: The member has a myeloid and/or lymphoid neoplasm with eosinophilia and JAK2 rearrangement in blast or chronic phase
    • Ruxolitinib availability or tolerance

      • Ruxolitinib (Jakafi) is unavailable
      • The member has experienced intolerance to ruxolitinib (Jakafi)
  1. There is no evidence of disease progression while on the current regimen
  2. Quantity limit30 per 30 days

    For myeloid and/or lymphoid neoplasms with eosinophilia and JAK2 rearrangement in blast or chronic phase, authorization requires that ruxolitinib (Jakafi) is unavailable or that the member has experienced intolerance to ruxolitinib.

    Documentation Required

    JAK2 Rearrangement Documentation

    Include testing or analysis confirming JAK2 rearrangement when applicable to the requested indication.

    • Submit the applicable laboratory, pathology, or molecular testing documentation with the prior authorization request.
    Denial Risk

    Criteria Not Met

    Ojjaara is considered not medically necessary when the member does not meet the applicable criteria set forth in the policy.

    • Requests that do not satisfy the initial-approval or applicable indication criteria may be denied.
    Denial Risk

    Toxicity or Disease Progression

    Continuation authorization is subject to the member remaining on the current regimen without clinically unacceptable outcomes.

    • For myelofibrosis, myelofibrosis-associated anemia, or myeloproliferative neoplasms: there must be no evidence of unacceptable toxicity.
    • For myeloid and/or lymphoid neoplasms with eosinophilia: there must be no evidence of unacceptable toxicity or disease progression while on the current regimen.
    • Continuation authorization may be granted for 12 months when the applicable continuation criteria are met.